Morgan T, Kofoed L, Petersen D B
Dept of Psychiatry, Royal C. Johnson VAMC, Sioux Falls, SD, USA.
S D J Med. 1996 Jun;49(6):195-200.
We investigated whether initiating a clinical pathway, that incorporated the use of an alcohol withdrawal assessment scale, would decrease length of stay (LOS) for and/or amount of benzodiazepine prescribed during uncomplicated alcohol detoxification. We retrospectively reviewed alcohol detoxification admissions on an inpatient unit: 66 admissions before, 56 after, and 75 admissions 1-year after initiation of the pathway. Admissions were grouped into completers and non-completers. Comparison of group means before and after pathway implementation demonstrated a significant decrease in LOS for completers of the detoxification service from 7.35 to 4.77 days, and from 6.67 to 4.31 days for all admissions. Similarly, total benzodiazepine exposure decreased to a third of the mg amount given per admission prior to the pathway. There were no increases in the "irregular" discharge rate or complication rate. These findings suggest that a clinical pathway, with an incorporated withdrawal assessment scale, can decrease LOS and benzodiazepine prescribing on an alcohol detoxification unit.
我们研究了启动一项纳入酒精戒断评估量表使用的临床路径，是否会缩短单纯酒精戒断期间的住院时间（LOS）和/或减少苯二氮䓬类药物的处方量。我们回顾性分析了一个 inpatient unit 上酒精戒断的入院病例：该临床路径启动前有66例入院病例，启动后有56例，启动后1年有75例。入院病例分为完成者和未完成者。对路径实施前后组均值的比较表明，戒毒服务完成者的住院时间从7.35天显著减少至4.77天，所有入院病例的住院时间从6.67天减少至4.31天。同样，苯二氮䓬类药物的总暴露量降至该路径实施前每次入院给药毫克数的三分之一。“非正常”出院率或并发症率没有增加。这些发现表明，一项纳入戒断评估量表的临床路径可以缩短酒精戒断科室的住院时间并减少苯二氮䓬类药物的处方量。 （注：“inpatient unit”此处翻译为“住院科室”等更符合语境的表述可能更好，但按照要求未添加额外说明，直接保留原文。）
